ClinicalTrials.gg
Active, not recruitingNCT06369467Updated Jun 26, 2026

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

A Phase 1 interventional study of linvoseltamab and dupilumab in Food Allergy, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.

Enrollment
97th of 105
6 · median 41
Started
2024
with 4 others
Phase 1
18 of 139
1 open now
Primary completion
2027-08
later than 13 of 27 live
Registered
124th of 139
by date

Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 97th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 in phase 1, reaches primary completion later than 13 of the 27 other live ones, and was the 124th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Food Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE antibodies are sent out by cells like plasma cells. These antibodies and allergens bind to other cells that send out chemicals, causing an allergic reaction. The aim of the study is to see what side effects happen when linvoseltamab is combined with dupilumab.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • Does linvoseltamab combined with dupilumab affect other types of antibodies in the blood at different times
  • How much study drug(s) is in the blood at different times
03

Conditions studied

  • Food Allergy

Browse trials for

Keywords

  • Severe Immunoglobulin E (IgE)-Mediated Food Allergy
  • Peanut
  • Hazelnut
  • Walnut
  • Cashew
  • Milk
  • Egg/egg white
  • Soy
  • Wheat
  • Sesame
  • Cod
  • Salmon
  • Tuna
  • Lobster
  • Crab
  • Shrimp
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical history of documented, ongoing, severe IgE-mediated allergy to food (peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp; documented symptom[s] of anaphylaxis due to exposure)
  2. History of physician reported anaphylaxis to food requiring epinephrine administration and/or requiring an emergency visit or inpatient hospitalization
  3. Participants with dupilumab-indicated atopic dermatitis (AD) must be receiving DUPIXENT as standard of care for the treatment of AD for a minimum of 12 weeks prior to screening OR Participants with dupilumab-indicated eosinophilic esophagitis (EoE) must be receiving DUPIXENT as standard of care for the treatment of EoE for a minimum of 12 weeks prior to screening OR Must be willing to initiate dupilumab treatment for food allergy
  4. Participants initiating dupilumab treatment must agree to remain on dupilumab for the duration of the combination study treatment and safety follow-up periods. Participants who elect to enter the linvoseltamab re-dosing period, must also remain on continuous dupilumab treatment as outlined. Participants on commercial DUPIXENT must agree to remain on their prescribed dose, as described in the protocol, for the duration of the combination study treatment period
  5. Participant must be willing to use an epinephrine auto-injector device
  6. Participant must be willing to receive booster and/or re-vaccination(s), including for live (attenuated) vaccinations, based on results of vaccine antibody titers and investigator opinion
  7. Has a between 18 and 32 kilogram per square metre (kg/m2), inclusive

Key Exclusion Criteria:

  1. Pregnant or breastfeeding women
  2. History of chronic disease (other than AD or EoE) requiring therapy (eg, heart disease, diabetes, hypertension) that, in the opinion of the principal investigator, would represent a risk to the participant's health or safety in this study or the participant's ability to comply with the study protocol. Participants on DUPIXENT for conditions other than AD or EoE (eg, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, etc) are excluded
  3. Known or suspected progressive multifocal leukoencephalopathy (PML), or history of PML, neurodegenerative condition, central nervous system (CNS) movement disorder, or seizure within 12 months prior to Day 1
  4. Recent history (within past 30 days) of a grade 3 or grade 4 gastrointestinal bleed, history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation
  5. History of moderate or severe asthma based on the Global Initiative for Asthma (GINA) guidelines
  6. Pre-bronchodilator (FEV1) \<80% of predicted using local reference values
  7. Any prior exposure to a B-cell maturation antigen (BCMA) targeted therapy
  8. Use of systemic within 2 months prior to screening
  9. Use of other forms of allergen immunotherapy (eg, oral, SC, patch, or sublingual) or immunomodulatory therapy (not including corticosteroids) within 4 months prior to screening
  10. Unwilling to discontinue use of antihistamines within 5 days prior to screening and within 5 days prior to skin prick test (SPT)
  11. to epinephrine and any of the in the epinephrine product
  12. Within the previous 2 months of the screening visit has a history of bacterial, protozoal, viral or parasite infection requiring hospitalization or treatment with IV anti-infectives
  13. Known history of (HIV) infection or HIV seropositivity at the screening visit

NOTE: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Severe IgE-mediated food allergy

    Drug: linvoseltamab · Drug: dupilumab

Interventions

  • Administered by intravenous (IV) infusion

    Also known as: REGN5458

  • Administered by subcutaneous (SC) injection

    Also known as: Dupixent®, REGN668

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

  2. Severity of TEAEs

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

  3. Incidence of Adverse Event of Special Interest (AESIs)

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

  4. Severity of AESIs

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

  5. Incidence of Serious Adverse Events (SAEs)

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

  6. Severity of SAEs

    Time frame: From the initial first dose of linvoseltamab through the end of week 30

Secondary outcomes

  1. Absolute change in the serum concentration of total IgE over time

    Time frame: Baseline to the end of week 30

  2. Percent change in the serum concentration of total IgE over time

    Time frame: Baseline to the end of week 30

  3. Time to reach unquantifiable total serum IgE concentration

    Time frame: Through the end of week 30

  4. Time to reach baseline level and/or the lower limit of the normal ranges of serum IgG

    Time frame: Through the end of week 30

  5. Time to reach baseline level and/or the lower limit of the normal ranges of serum immunoglobulin M (IgM)

    Time frame: Through the end of week 30

  6. Time to reach baseline level and/or the lower limit of the normal ranges of serum immunoglobulin A (IgA)

    Time frame: Through the end of week 30

  7. Incidence of participants with unquantifiable concentrations of serum total IgE

    Time frame: Through the end of week 30

  8. Absolute change in the serum concentration of food allergen-specific IgE

    In participants who tested positive for a measured food allergen-specific IgE at baseline

    Time frame: Baseline through the end of week 30

  9. Percent change in the serum concentration of food allergen-specific IgE

    In participants who tested positive for a measured food allergen-specific IgE at baseline

    Time frame: Baseline through the end of week 30

  10. Time to reach unquantifiable food allergen-specific serum IgE levels

    In participants who tested positive for a measured food allergen-specific IgE at baseline

    Time frame: Through the end of week 30

  11. Incidence of TEAEs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

  12. Severity of TEAEs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

  13. Incidence of AESIs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

  14. Severity of AESIs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

  15. Incidence of SAEs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

  16. Severity of SAEs

    Time frame: Following the combination study treatment period up to approximately 176 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Aug 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 17, 2024
StartActual
May 17, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06369467
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
May 17, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion